SLU-PP-332 Community Sourcing Queries and Catalogue Token Resolution: A Research Review of ERR Pan-Agonist Identity, Orthographic Variant Taxonomy and the Resolution of "slu pp peptide", "slupp-332", "slubam" and "slu po 332" Labels

By the Peptide Insider Research Desk

Catalogue searches for the synthetic ERR pan-agonist SLU-PP-332 generate dozens of query variants—slu pp peptide, slupp-332, slu po 332, slubam, slu pp32, slu 332 peptide and what is slu pp 332 peptide among them—that fragment community discussions and complicate literature retrieval. This review maps every common search token to the single canonical identity registered under CAS 303760-60-3, classifies each by orthographic error mechanism, and assigns an explicit research-use-only (RUO) scope status. All content below is strictly for research reference; not for human or veterinary use.

Is SLU-PP-332 a Peptide? Structural Classification

A recurrent community query—is slu pp 332 a peptide and its hyphenated variant is slu-pp-332 a peptide—reflects the compound's unusual positioning in research-supply catalogues alongside genuine peptides [1]. SLU-PP-332 is a diarylhydrazide: two aryl rings connected by a hydrazide (–CO–NH–NH–) linker. It lacks the amide-backbone repeat (–NH–CHR–CO–) that defines peptides. Its molecular weight (290.32 Da) sits well below the conventional 500 Da cut-off used by pharmacopeial classifications, and its synthesis proceeds via Suzuki coupling rather than solid-phase peptide synthesis [2,3]. Catalogues list it alongside peptides because its phenotypic readout—ERR-dependent fibre-type switching and mitochondrial biogenesis—intersects the same experimental space as peptide slu pp 332-related search terms imply, despite the structural divergence.

Orthographic Error Taxonomy: Mapping Community Query Tokens

The laboratory-style alphanumeric name "SLU-PP-332" invites at least six classes of transcription error when researchers type catalogue searches. The table below classifies every documented variant by error mechanism and assigns an RUO scope status. Strings in the "Declined" rows reference dosage protocols, purchasing channels or promotional codes that fall outside research-nomenclature scope.

ERR Pan-Agonist Mechanism: PGC-1α Recruitment and Fibre-Type Switching

SLU-PP-332 activates all three estrogen-related receptor isoforms with sub-micromolar potency: EC₅₀ values of 98 nM (ERRα), 230 nM (ERRβ) and 430 nM (ERRγ) have been reported in cell-based transcriptional assays [1]. Ligand binding stabilises the AF-2 surface of each receptor, promoting recruitment of the transcriptional co-activator PGC-1α (peroxisome proliferator-activated receptor gamma co-activator 1-alpha) [1,4]. PGC-1α in turn drives a gene-expression programme centred on mitochondrial biogenesis: increased transcription of cytochrome c, electron-transport-chain complexes I and V, and mitochondrial DNA replication factors [1,5].

In C2C12 murine myotubes, treatment with SLU-PP-332 increased cellular oxygen consumption rate (OCR)—a proxy for mitochondrial respiration—by approximately 40% relative to vehicle control [1]. The functional consequence in vivo is a shift in skeletal-muscle fibre composition from fast-twitch glycolytic (Type IIb) toward slow-twitch oxidative (Type I) fibres, a phenotype classically associated with endurance training [1,6]. Rangwala and colleagues demonstrated as early as 2010 that ERRγ is a key regulator of muscle oxidative capacity, providing the mechanistic foundation for the fibre-type switching observed with pan-ERR agonism [4].

Preclinical Evidence Table

Chemical Optimisation and Next-Generation Analogues

Okda and colleagues (2026) reported systematic structural modifications to the SLU-PP-332 scaffold, varying the diarylhydrazide core and peripheral substituents to explore structure-activity relationships across the ERR family [3]. Their work confirmed that the hydrazide linker is essential for receptor engagement and that steric constraints on the distal aryl ring modulate isoform selectivity. A key outcome of this programme was SLU-PP-915, an orally active analogue that retains pan-ERR agonism while exhibiting improved pharmacokinetic properties in murine models [7]. Billon et al. (2026) demonstrated that SLU-PP-915 enhances aerobic exercise capacity when administered orally, an advance over SLU-PP-332 whose in vivo studies have relied on intraperitoneal injection [7].

Anti-Doping and Regulatory Context

The exercise-mimetic properties of SLU-PP-332 have attracted regulatory scrutiny. The World Anti-Doping Agency (WADA) classifies metabolic modulators and exercise mimetics as prohibited substances under Section S4.5 of the Prohibited List. In anticipation of potential misuse, two independent groups have characterised the in vitro phase I and phase II metabolites of SLU-PP-332 using human liver microsomes and recombinant CYP isoforms [8,9]. Moller et al. identified hydroxylated and N-dealkylated metabolites suitable for urine-based screening, while Avliyakulov and colleagues developed a complementary liquid-chromatography high-resolution mass-spectrometry method targeting glucuronide conjugates [8,9]. These analytical frameworks enable retrospective detection in biological samples, underscoring that SLU-PP-332 is a regulated research tool, not an unmonitored supplement.

Frequently Asked Questions

What is SLU-PP-332 peptide and is it actually a peptide?

SLU-PP-332 (CAS 303760-60-3) is a small-molecule diarylhydrazide, not a peptide. It contains no peptide bonds and has a molecular weight of 290.32 Da. It appears in peptide-research catalogues because its ERR-agonist biology overlaps with peptide growth-hormone secretagogue research applications [1,2].

What do search terms like slu pp peptide, slupp-332 and slu po 332 refer to?

These are orthographic variants of SLU-PP-332. Hyphen elision (slu pp peptide), whitespace collapse (slupp-332) and vowel substitution (slu po 332) are common transcription errors in catalogue search bars. All resolve to a single compound: CAS 303760-60-3 [1].

What is slubam?

The term slubam is a portmanteau or autocorrect artefact that maps to SLU-PP-332 in research-catalogue search logs. It has no independent chemical meaning.

What does SLU-PP-332 do in preclinical models?

In murine studies, SLU-PP-332 activates ERRα/β/γ, recruits PGC-1α and drives mitochondrial biogenesis. Observed phenotypes include fast-to-slow muscle-fibre switching, increased running endurance (+70% distance) and improved metabolic markers in diet-induced obese mice [1,2].

Is SLU-PP-332 powder the same compound as SLU-PP-332 tablets or capsules?

Catalogue terms like slu pp 332 powder, slu pp 332 tablets and slu pp 332 500mcg describe different form-factor presentations of the same compound (CAS 303760-60-3, MW 290.32). The active molecule is identical; only the physical format and fill mass differ [1].

Where to Source SLU-PP-332 for Research

Investigators procuring SLU-PP-332 for in vitro or in vivo studies should verify supplier certificates of analysis (CoA) against the canonical molecular formula (C₁₈H₁₄N₂O₂) and confirm purity by HPLC. Short Chain Aminos maintains research-grade catalogue listings with third-party analytical verification. Additional supplier options include BioPep for bulk-format research quantities, Catalyst Research for lyophilised reference standards, and Apex Research Services for multi-compound study kits. No vendor has been assessed or endorsed by this publication; researchers should perform independent due diligence on analytical documentation before procurement.

Works Cited

1. Billon C, Sigafoos AN, Lussier AM, et al. Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol. 2023;18(4):756-771. PMID: 36988910.
2. Billon C, Draft K, Lussier AM, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther. 2024;388(2):232-240. PMID: 37739806.
3. Okda HE, et al. Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling. Int J Biol Macromol. 2026. PMID: 41850449.
4. Rangwala SM, Wang X, Calvo JA, et al. Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity. J Biol Chem. 2010;285(29):22619-22629. PMID: 20418374.
5. Soriano FX, Liesa M, Bach D, et al. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes. 2006;55(6):1783-1791. PMID: 16731843.
6. Bonanni R, et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol. 2025;16:1616693. PMID: 40692696.
7. Billon C, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026. PMID: 41421047.
8. Moller T, et al. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential. Rapid Commun Mass Spectrom. 2026. PMID: 41588687.
9. Avliyakulov NK, et al. Analysis and identification of in vitro metabolites of exercise mimetic SLU-PP-332 ERRα/β/γ agonist for doping-control purposes. Drug Test Anal. 2026. PMID: 41688415.
10. de Souza-Lima J, et al. Pharmacological activation of ERRα/β/γ as an exercise mimetic: potential therapeutic applications. Rev Med Chil. 2026. PMID: 42024694.
11. Huang X, et al. Estrogen deficiency induces pelvic floor muscle atrophy via ERRα/GLUT4 pathway. PLoS One. 2026. PMID: 42133665.
12. Zhao P, et al. Anabolic effect of tanshinone IIA on myotube hypertrophy is mediated by estrogen receptor. Planta Med. 2015;81(7):578-585. PMID: 26018796.
13. Valero T. Mitochondrial biogenesis: pharmacological approaches. Curr Pharm Des. 2014;20(35):5507-5509. PMID: 24606795.

This article is strictly for research reference; not for human or veterinary use. No dosage guidance, therapeutic recommendation or clinical instruction is provided or implied. Researchers should consult institutional review protocols before initiating any study.